Submitted by Sabin on
Today Chagas disease is one of the world’s most important neglected tropical diseases (NTDs) and a leading cause of poverty in Latin America. An estimated 10 million people are infected worldwide with more than 99% of the cases occurring in Latin America, especially in the poorest countries in the region.
The Sabin PDP is currently engaged in collaboration for early research and development for a bivalent therapeutic vaccine for the treatment of chronic Chagas disease (American trypanosomiasis). It would be the first therapeutic vaccine for this disease. The vaccine is comprised of two Trypanosoma cruzi recombinant proteins formulated on alum. One of the antigens is a unique T. cruzi 24 kDa antigen (Tc24) and the other is a unique T. cruzi surface transialidase (TSA-1).
With over a decade of experience, Sabin PDP has produced a well-rounded model that serves as a blueprint for the development of safe and effective vaccines against vaccine preventable and neglected tropical diseases. Existing capabilities include:
Product Development: Established the infrastructure to engage in antigen discovery, rapid development of scalable manufacturing processes (process development), quality control, preclinical and clinical immunology and stability testing.
